Akebia Therapeutics (AKBA) Shares Outstanding (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Shares Outstanding (Entity) of $267.9 million for Q1 2026, up 2.39% year-over-year from $261.6 million in Q1 2025, and up 0.93% quarter-over-quarter from $265.4 million in Q4 2025.
Akebia Therapeutics (AKBA) Shares Outstanding (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Shares Outstanding (Entity) for 14 consecutive years, with $267.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.39% year-over-year to $267.9 million; the TTM figure through Mar 2026 stood at $267.9 million (up 2.39% YoY), while the FY2025 annual figure was $265.4 million, up 18.05% from the prior year.
- Shares Outstanding (Entity) rose to $267.9 million in Q1 2026 per AKBA's latest filing, from $265.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $267.9 million in Q1 2026 and bottomed at $183.4 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $215.9 million across 5 years, with a median of $209.5 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 1.34% — and 2025, when it gained 25.38%.
- Akebia Therapeutics' Shares Outstanding (Entity) stood at $184.1 million in 2022, then advanced by 5.67% to $194.6 million in 2023, then gained by 15.55% to $224.8 million in 2024, then grew by 18.05% to $265.4 million in 2025, then climbed by 0.93% to $267.9 million in 2026.
- Business Quant data shows AKBA's Shares Outstanding (Entity) at $267.9 million in Q1 2026, $265.4 million in Q4 2025, and $265.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 832.44 Mn |
| 10 | Akebia Therapeutics | 240.51 Mn | 84.96 Mn | 38.70 Mn | 269.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 269.60 Mn |
| Mar 31, 2026 | 267.05 Mn |
| Dec 31, 2025 | 257.16 Mn |
| Sep 30, 2025 | 264.79 Mn |
| Jun 30, 2025 | 262.57 Mn |
| Mar 31, 2025 | 235.50 Mn |
| Dec 31, 2024 | 210.95 Mn |
| Sep 30, 2024 | 210.35 Mn |
| Jun 30, 2024 | 209.71 Mn |
| Mar 31, 2024 | 204.96 Mn |
| Dec 31, 2023 | 187.47 Mn |
| Sep 30, 2023 | 188.31 Mn |
| Jun 30, 2023 | 186.82 Mn |
| Mar 31, 2023 | 184.77 Mn |
| Dec 31, 2022 | 182.78 Mn |
| Sep 30, 2022 | 183.88 Mn |
| Jun 30, 2022 | 183.60 Mn |
| Mar 31, 2022 | 179.60 Mn |
| Dec 31, 2021 | 165.95 Mn |
| Sep 30, 2021 | 173.78 Mn |